Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.

NCT06434610 is registered in ClinicalTrials.gov with Shanghai Jiaolian Drug Research and Development Co., Ltd as lead sponsor.

NCT NCT06434610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06434610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.
Lead sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
July 11, 2024
Completion date
December 31, 2026
Enrollment
90 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant recurrent ovarian cancer